AngioSoma, Inc.
Skip to content
  • Home
  • About Us
    • Management
    • Scientific Advisory Board
  • Pipeline
    • Liprostin™
      • PAD
      • PGE-1
      • Ulcerations
    • Transdermal PGE-1 Patch
    • OmniCath I & II
    • Nutraceuticals
  • Subsidiaries
    • AngioSoma Research Inc.
    • SOMA Nutraceuticals, Inc.
  • Investors
    • Management
    • News
    • SEC Filings
    • SEC Section 16 Reporting
    • Investor FAQ
    • Investor Tools
      • BoardCentral
      • Investors Hangout
  • News
  • Contact Us

alex-blankenship-ceo-angiosoma

Posted on November 25, 2016 by Thomas Clayy

This entry was posted in . Bookmark the permalink.

Post navigation

← alex-blankenship-ceo-angiosoma

Recent Posts

  • AngioSoma, Inc. (OTC: SOAN) Reports Esther & Esther Confident in New Revenue Plan
  • AngioSoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to Maximize Sales of Its OTC Products with Existing Online Marketing Platform
  • AngioSoma, Inc. Starts SOMA Nutraceuticals, Inc.’s Operations
  • November 2016 Shareholder Presentation
  • AngioSoma, Inc. Acquires Patented Nutraceutical for Muscle Mass Development

Follow me on Twitter

My Tweets

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org
14001 Walden Rd., Ste. 600 Montgomery, TX 77356 USA
investors@angiosoma.info
(832) 781-8521
  • Go to Twitter
  • Go to Linkedin

© 2017 by AngioSoma, Inc., all rights reserved.

Zerif Lite powered by WordPress